相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- A single-center cohort study of 98 polymyxin B treatment episodes found clinical cure was significantly less frequent in high-MIC (>1 mg/L) versus low-MIC (≤1 mg/L) carbapenem-resistant Enterobacterales infections (27.0% vs. 55.7%, P = 0.007). - Polymyxin B MIC >1 mg/L was independently associated with lower odds of clinical cure after multivariable adjustment (adjusted OR = 0.311; 95% CI, 0.119–0.809; P = 0.017). - Pharmacokinetic/pharmacodynamic target attainment (AUC/MIC ≥50) was markedly lower in the high-MIC group (13.5%) than the low-MIC group (90.2%, P < 0.001), driven by the higher MIC denominator rather than reduced systemic exposure. - The findings support using a PMB MIC >1 mg/L threshold for clinical risk stratification and provide hypothesis-generating evidence for prospective breakpoint evaluation.
- The phase 2b TERRIFIC study demonstrated that adding tislelizumab to chemoradiotherapy achieved a 25.7% pathologic complete response rate compared to 18.2% with chemoradiotherapy alone and 5.3% with chemotherapy alone in gastric cancer patients. - Among patients who underwent surgery, the combination therapy achieved a 32.1% pathologic complete response rate and 67.9% major pathologic response rate, substantially higher than either control arm. - Treatment-related adverse events were manageable across all arms, with grade 3 or higher events occurring in 31.4% of combination therapy patients versus 24.2% and 15.8% in the control groups. - This represents the first randomized comparison of three neoadjuvant strategies for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.
- Researchers developed machine learning models using systemic inflammation markers to predict pathological complete response (pCR) after neoadjuvant chemotherapy in breast cancer patients. - The Random Forest algorithm achieved the best performance with the lowest error rate (RMSE 0.109) and highest correlation (r=0.94) when predicting treatment response. - Lower neutrophil-to-lymphocyte ratio (NLR), higher lymphocyte-to-monocyte ratio (LMR), and absence of lymph node metastasis were identified as independent predictors of better treatment outcomes. - The predictive model demonstrated strong clinical utility with potential to guide personalized treatment decisions for breast cancer patients undergoing neoadjuvant therapy.
